anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain liposome which is fine, stable and capable of use for biological applications by forming a wall film consisting of substance selected from among rhamnolipid A, rhamnolipid B and their neutral salts. CONSTITUTION:Rhamnolipid A and rhamnolipid B shown in a formula I and a formula II are a microbe-derived biosurfactant and are one kind of glycolipids. These perform the conversion of a molecular association type reversible among micell-droplet-lamella-vehicle (closed follicle) which is dependent on pH. In other words, a micell is formed at pH not less than 6.8 (complete neutral salt) and a lamella-shape is formed at 6.5-6.0pH and they are converted into a vehicle at 5.8-4.3pH. Liposome is formed from rhamnolipid A and rhamnolipid B by a well-known method by utilizing these properties. The obtained liposome is fine and stable and can be used for biological applications.
Several studies have reported that diabetic subjects have lower plasma vitamin C concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic subjects was reported to be increased in two studies, these are difficult to interpret due to lack of controlled vitamin C intake, inadequate sampling, lack of control subjects, or methodology uncertainties in vitamin C assay and sample processing. Consequently, it is unclear whether diabetic subjects truly have both low plasma and high urine vitamin C concentrations. We propose that low plasma vitamin C concentrations in diabetic subjects are due in part to inappropriate renal loss of vitamin C in these subjects but not in healthy controls. We will study nondiabetic controls and cohorts with diabetes. Vitamin C concentrations in plasma, RBCs, and urine will be measured in outpatients. In those willing to be admitted to the Clinical Center, we will measure vitamin C pharmacokinetics to determine the relative bioavailability for vitamin C in individuals with and without abnormal urinary loss of vitamin C (or renal leak). Single nucleotide polymorphisms (SNPs) will be determined in genomic DNA responsible for the two proteins mediating sodium dependent vitamin C transport, SVCT1 and SVCT2. We will also explore mechanisms underlying abnormal urinary vitamin C loss.
OBJECTIVE: Genome-wide association studies have identified 1q22 as a susceptibility locus for cerebral small vessel diseases, including non-lobar intracerebral hemorrhage (ICH) and lacunar stroke. In the present study, we performed targeted high-depth sequencing of 1q22 in ICH cases and controls to further characterize this locus and prioritize potential causal mechanisms, which remain unknown.
METHODS: A total of 95,000 base pairs spanning 1q22, including SEMA4A, SLC25A44, and PMF1/PMF1-BGLAP were sequenced in 1,055 spontaneous ICH cases (534 lobar and 521 non-lobar) and 1,078 controls. Firth regression and Rare Variant Influential Filtering Tool analysis were used to analyze common and rare variants, respectively. Chromatin interaction analyses were performed using Hi-C, chromatin immunoprecipitation followed by sequencing, and chromatin interaction analysis with paired-end tag databases. Multivariable Mendelian randomization assessed whether alterations in gene-specific expression relative to regionally co-expressed genes at 1q22 could be causally related to ICH risk.
RESULTS: Common and rare variant analyses prioritized variants in SEMA4A 5'-UTR and PMF1 intronic regions, overlapping with active promoter and enhancer regions based on ENCODE annotation. Hi-C data analysis determined that 1q22 is spatially organized in a single chromatin loop, and that the genes therein belong to the same topologically associating domain. Chromatin immunoprecipitation followed by sequencing and chromatin interaction analysis with paired-end tag data analysis highlighted the presence of long-range interactions between the SEMA4A-promoter and PMF1-enhancer regions prioritized by association testing. Multivariable Mendelian randomization analyses demonstrated that PMF1 overexpression could be causally related to non-lobar ICH risk.
INTERPRETATION: Altered promoter-enhancer interactions leading to PMF1 overexpression, potentially dysregulating polyamine catabolism, could explain demonstrated associations with non-lobar ICH risk at 1q22, offering a potential new target for prevention of ICH and cerebral small vessel disease. ANN NEUROL 2024;95:325-337.
FIELD: biotechnology, veterinary science. SUBSTANCE: invention relates to production of vaccine preparations against pyocyanic infection in fur wild animals, mainly, in polar foxes and foxes. Strain of bacterium Pseudomonas aeruginosa is deposited in collection of strains that are pathogens of diseases in fur wild animals of museum of bacterial and viral cultures of Science- Research institute of fur farming and rabbit breeding (NIIPZK) named for V. A. Afanasiev and has registration number 449 2 . Strain relates to serovariant 03. Strain is cultured in Marten's broth or synthetic medium at 32 C for 18-20 h at constant shaking. After control of grown culture for toxicogenicity and proteolytic activity bacterial mass is separated and inactivated, aluminum hydroxide is added as an adjuvant and packaged. Invention ensures to prevent the concealed loss in fur wild animals reproduction in farms with pyocyanic infection being independently of serological pattern of pathogen. EFFECT: strain indicated above, enhanced effectiveness of vaccine.
PURPOSE: A composition for preventing and treating bone diseases is provided to reduce differentiation or activation of osteoclast, to suppress bone resorption, and to promote differentiation of osteoblast and osteogenesis. CONSTITUTION: A composition for preventing or treating bone diseases contains a Rumex crispus L. extract as an active ingredient. The extract is prepared using a solvent selected from the group consisting of water, hydrous or anhydrous C1-C4 alcohol, acetone, ethyl acetate, butyl acetate, dichloromethane(CH_2Cl_2), chloroform(CHCl_3), hexane, and 1,3-butylene glycol. Bone diseases are bone damage, osteoporosis, osteomalacia, richets, osteitis fibrosa, aplastic bone disease, or metabolic bone disease. The extract promotes differentiation of osteoblast. A pharmaceutical composition for preventing or treating bone diseases contains a pharmaceutically effective amount of the composition and a pharmaceutically acceptable carrier.
PURPOSE:To obtain the titled substance containing specific fibrous materials after extracting and sufficiently removing soluble ingredients from beets as an active ingredient. CONSTITUTION:Beets are cut into the form of small pieces or ground and pressed to squeeze juice therefrom. The pressed pieces are then dipped in hot water to sufficiently extract and remove soluble ingredient consisting essentially of the beets. The resultant residue free of the soluble ingredient is then subjected to treatment, such as decoloring, deodorizing, drying and pulverizing to afford a substance containing fibrous materials (the fibrous material consist of cellulose, hemicellulose and pectin accounts for about 70% based on the total solid substance at 1:1:1 ratio of cellulose:hemicellulose:pectin). The above-mentioned fibrous materials are contained as an active ingredient to provide an improving substance for liquid metabolism. This substance is capable of suppressing increase of cholesterol and neutral fat in blood serum and accumulation of cholesterol and fat in the liver. The afore-mentioned fibrous material may be fractionated and granulated with an excipient or directly added to various drinks and foods.
This is a prospective, randomised, assessor-blinded, single centre study. Patients with symptomatic coronary artery diseases in 2 or 3 coronary vessels requiring PCI are eligible for the study. PCI will be performed in the usual manner to all the study lesions in the same procedure. In a randomized fashion, each patient will have one artery with critical disease(s) treated by the Resolute Integrity Stent(s) and the other artery treated by the Biomatrix Stent(s).

Baseline OCT data will be obtained right after stenting. The remaining coronary artery, if diseased and required PCI treatment, will be treated during the angiographic and OCT follow-up as a staged procedure. Patients will be randomly assigned into 5 groups with equal number, receiving a follow-up coronary angiogram with OCT from 2, 3, 4, 5 and 6 months interval post-intervention. Each patient will serve as his/her own control comparing the 2 types of stents. At 9-month post-intervention, all patients will receive a second follow-up coronary angiogram with OCT. All OCT data analyses will be performed in a blinded fashion by a core laboratory. Phone follow up will be carried out for cardiac events at 1 year and 2 year of post intervention.
The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions. Participants with PSA\<1.5ng/ml are reinvented for prescreen after 6 years. Remaining participants with no prostate cancer detected are reinvited for re-screen at 2-3 years.
Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
Stroke is the leading cause of long-term disability and the second most common cause of death worldwide, accounting for around 6.7 million deaths each year. The burden of stroke due to illness, disability and early death is set to double within the next 15 years due to an ageing population. Currently, imaging techniques are required to differentiate ischemic strokes with large vessel occlusion (LVO) from others. Since those neuroimages cannot be easily done at a pre-hospital level, our objective is to develop a simple point-of-care test (POC) to differentiate between both ischemic strokes during the acute phase, which will allow in the future an earlier thrombectomy treatment and an improvement of the patient outcomes significantly. For that, the investigators will recruit a 800 patients' cohort with pre-hospital and in-hospital blood samples by a multiplex POC for the biomarker measurement using an APP in combination with clinical data to identify LVO ischemic strokes. Finally, an interim analysis is planned when 400 patients are recruited.
Consecutive patients with ANP presenting to the hospital within 2 weeks from the pain onset will be recruited. They will undergo serial non-contrast MRI starting at day 15 and every 5 days thereafter, till complete encapsulation of PFC. Ultrasound evaluation of the collection will be performed on the day of MRI by a radiologist not involved in evaluation of MRI. The site and volume of collection as well as thickness and completeness of the capsule and solid content within the collection will be recorded independently by two radiologists. The timing of clinically significant (\>50% of PFC show capsule) and complete encapsulation will be recorded. The proportion of collections encapsulating in each week after 2nd week of illness will be recorded. The association between timing of encapsulation and clinical/biochemical parameters will be assessed. The correlation between the degree of encapsulation and percentage of solid components will also be documented. Multivariate analysis will be performed to identify factors associated with timing of encapsulation.
Participants will ingest 3 ounces of vodka mixed with fruit juice within 30 min. Then provocative concentration causing a 20% fall in forced expiratory volume in 1 s (PC20FEV1) will be measured. A one-half concentration difference in the PC20FEV1 will be considered a statistically significant change in airway hyperresponsiveness.
Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
Methods and apparatus, including computer program products, are provided for processing analyte data. In some exemplary implementations, there is provided a method. The method may include generating, by at least one processor, a view comprising an abstraction distilled from the sensor data over a time period. The view may further comprise a graphical representation comprising a plurality of different graphically distinct elements representative of whether the abstraction over the time period is at least one of at, above, or within a predetermined glucose concentration level for a host; a call out comprising value help for the graphical representation, and a textual legend comprising a description of the graphical representation and the abstraction. The method may further include providing the view as a module. Related systems, methods, and articles of manufacture are also disclosed.
Biodegradable neurotoxin implants and methods of malting and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.
The loss of semaphorin 3A (Sema3A), which is related to endothelial-to-mesenchymal transition (EndMT) in atrial fibrosis, is implicated in the pathogenesis of atrial fibrillation (AF). To explore the mechanisms by which EndMT affects atrial fibrosis and assess the potential of a Sema3A activator (naringin) to prevent atrial fibrosis by targeting transforming growth factor-beta (TGF-β)-induced EndMT, we used human atria, isolated human atrial endocardial endothelial cells (AEECs), and used transgenic mice expressing TGF-β specifically in cardiac tissues (TGF-β transgenic mice). We evaluated an EndMT marker (Twist), a proliferation marker (proliferating cell nuclear antigen; PCNA), and an endothelial cell (EC) marker (CD31) through triple immunohistochemistry and confirmed that both EndMT and EC proliferation contribute to atrial endocardial fibrosis during AF in TGF-β transgenic mice and AF patient tissue sections. Additionally, we investigated the impact of naringin on EndMT and EC proliferation in AEECs and atrial fibroblasts. Naringin exhibited an antiproliferative effect, to which AEECs were more responsive. Subsequently, we downregulated Sema3A in AEECs using small interfering RNA to clarify a correlation between the reduction in Sema3A and the elevation of EndMT markers. Naringin treatment induced the expression of Sema3A and a concurrent decrease in EndMT markers. Furthermore, naringin administration ameliorated AF and endocardial fibrosis in TGF-β transgenic mice by stimulating Sema3A expression, inhibiting EndMT markers, reducing atrial fibrosis, and lowering AF vulnerability. This suggests therapeutic potential for naringin in AF treatment.
Gemfibrozil tablet, USP is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil. Each also contains colloidal silicon dioxide, PEG 3000, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, polyvinyl alcohol, pregelatinized starch, sodium starch glycolate, talc, titanium dioxide. The chemical name is 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid, with the following structural formula:

The empirical formula is C15H22O3 and the molecular weight is 250.35; the solubility in water and acid is 0.0019% and in dilute base it is greater than 1%. The melting point is 58°-61°C. Gemfibrozil is a white solid which is stable under ordinary conditions.
Described herein is using cryptographic techniques (anonymous proof systems) to ensure the anonymity of health records when processing payment claims related to insurers and pharmacies. A patient receives a patient token from an insurer, which the patient delegates to a healthcare provider. The delegated token is processed into an anonymized token that identifies the healthcare provider and the medical service provided, without including information by which the patient is directly identifiable. The anonymized token includes data by which the insurer validates the token. For prescriptions, an anonymized token may be generated as an endorsement for the patient (e.g., a printed barcode) and an unendorsed token transmitted to the pharmacy. The pharmacy combines data of the endorsement and the unendorsed token into an anonymous combined token that is transmitted to the insurer for payment.
Several studies have shown that high protein diet can reduce body fat, increase muscle mass, and improve some metabolic parameters of subjects. Also, several studies have shown that high intake of fiber could reduce body weight and improve cardiometabolic parameters. Therefore, combining high-protein diet and high-fiber diet should have a positive synergistic effect on several of anthropometric and metabolic parameters. The aims of this study is to investigate the effect of eucaloric high protein and fiber diet on healthy subjects. Thirteen healthy subjects, age 29,85 ± 4,06 years old, with body mass index (BMI) 29,55 ± 4,12 kg/m2 were prescribed eucaloric high protein diet for two weeks, followed by washing period for two week. Then, they were prescribed with eucaloric high protein and high fiber diet for two more weeks. Twenty grams of dietary fiber were in the form of isomaltooligosaccharides (IMO) based creamer formulae. Their body composition, waist circumference, fasting blood glucose, blood uric acid and total cholesterol concentration were measured after every dietary intervention.
The present invention discloses acupoint selection and sticking compress medicine for treating chronic bronchitis and bronchial asthma, which is mainly prepared from the medicinal components of yam, musk, pinellia tuber, arisaema cum bile, asarum, white mustard seed, kansui root, etc. The medicinal components are pulverized and sieved into powder and are prepared into a paste with ginger juice and azone according to the weight preparing ratio of 5 to 1 to 0.3. The medicine of the present invention uses the method of combining a syndrome differentiation type and a syndrome differentiation acupoint selection medicine sticking compress type to treat cough and asthma. The medicine of the present invention achieves the aims of coordinating Yin and Yang and resisting pathogenic factors through stimulating acupuncture points, dredging the channel and conditioning Qi and blood. The medication directly reaches disease parts, and pharmacological action is played through the divergence, the spread and the percutaneous absorption of the medication. The medicine has the advantages of convenient use, peculiar curative effect and no side effect and belongs to simple, convenient, cheap and tested medicine for treating cough and asthma.
Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks. The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD. The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD. Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi. Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing. Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
PURPOSE:To provide the titled thickener containing a specific polycarboxylic acid copolymer and a crosslinked polyacrylic acid at a specific ratio. CONSTITUTION:The objective thickener for poultice is prepared by compounding (A) a polycarboxylic acid copolymer having a pH of <=8 and obtained by the polymerization of two kinds of monomers selected from the compounds of formula (R is H, COOH, etc.; R1 is H, CH3, etc.; R2 is H or alkali metal) or their salts and (B) a crosslinked polyacrylic acid having a viscosity of >=400cps as 0.2wt% aqueous solution of the product neutralized completely with NaOH, using a Brookfield viscometer (20 deg.C, 30rpm). The amount of the component B is 10-70wt%, preferably 15-60wt% based on the total amount of the component A. The thickener has excellent adhesivity and water-retainability, and keeps the drug component stably for a long time. The amount of the thickener added to the poultice composition is 0.5-15wt%.
The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Aβ) protein or peptide. Anti-Aβ antibodies are selected and sequenced. In certain embodiments, synthetic Aβ binding peptides are designed and prepared, using portions of the anti-Aβ antibody sequences. The antibodies and peptides are of use for treatment of AF or for treatment of individuals at risk of developing AD. Compositions comprising anti-Aβ antibodies or Aβ binding peptides are also disclosed.
People with prolonged musculoskeletal disorders have impaired quality of life, physical function, work conditions and work ability and consume substantial public resources. An often overlooked fact in this context is the relationship between musculoskeletal disorders and the importance of a normally functioning visual system. People who have a visual impairment in adulthood often experience reduced health and life satisfaction. Many people lose their faith in order to continue with the activities previously carried out as to cope with their life, their work, and in some cases,personal care. Rehabilitative efforts to reduce the negative effects often involve the prescription of various visual aids which, in turn, often leads to unfavourable ergonomic and static postures with further increased risk of musculoskeletal problems. A prevention of such disorders is likely to allow them to continue their work, which is important from both an individual and a society perspective. The overall objective of the project is to evaluate the effects of an intervention program and develop a theoretical model for the relationship between near work, eye disorders and musculoskeletal disorders. The intervention is to be evaluated in a randomized trial on people with impaired vision and pain in the neck and scapular area. An intervention based on development and adaptation of an established physiotherapy practice in order to increase body awareness, body control and movement patterns will be evaluated. The effects of the intervention will be measured by a variety of outcome measures derived from WHO's ICF-model. An innovative solution for establishing proprioception and eye-hand coordination in everyday activities, the Clinical Kinematic Assessment Tool, will be used.